Jump Financial’s Tvardi Therapeutics TVRD Stock Holding History

Jump Financial’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-628	Closed	-$64K	–	2332
2023 Q2	$64K	Buy	+628	New	+$86.5K	﹤0.01%	1710
2022 Q4	–	Sell	-978	Closed	-$329K	–	2099
2022 Q3	$329K	Sell	978 -230	-19%	-$83.3K	0.01%	1100
2022 Q2	$397K	Sell	1,208 -336	-22%	-$118K	0.02%	944
2022 Q1	$675K	Buy	+1,544	New	+$634K	0.03%	678
2021 Q4	–	Sell	-1,194	Closed	-$664K	–	1786
2021 Q3	$664K	Buy	+1,194	New	+$599K	0.05%	407

Other funds holding TVRD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return

Jump Financial's TVRD Position: Q3 2023 in Review

Jump Financial sold out of Tvardi Therapeutics (TVRD) in Q3 2023, closing a stake of 628 shares — an estimated $64K sold.

Jump Financial first reported a position in TVRD in Q3 2021 and held it in 5 quarters. The position peaked at $675K in Q1 2022. 122 funds tracked by Wall St. Rank hold TVRD as of Q3 2023.

Jump Financial reported no remaining Tvardi Therapeutics position as of Q3 2023 after selling out during the quarter.
Jump Financial sold 628 Tvardi Therapeutics shares in Q3 2023, an estimated $64K.
Jump Financial first reported a position in Tvardi Therapeutics in Q3 2021 and held it in 5 quarters.
Jump Financial's Tvardi Therapeutics position peaked at $675K in Q1 2022.
122 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2023.

Based on Jump Financial's 13F filing for Q3 2023, filed 7 Nov 2023.